The Drug-Induced Respiratory Disease Website and App

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.f Severe or catastrophic bronchospasm or asthma attack (can be fatal)

V. Pleural and/or pericardial involvement

V.e Hemothorax - Serosanguineous pleural effusion

VII. Mediastinal involvement

VII.b Lymphadenopathy with reactive changes

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.y Sinonasal discharge, -blockage, -obstruction

X. Systemic/Distant conditions, syndromes and reactions

X.h Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.q Systemic inflammatory response

XI. Miscellaneous

XI.d Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

XI. Miscellaneous

XI.as Pharmacobezoar

XI. Miscellaneous

XI.az Sneezing (may cause pulmonary barotrauma)

XII. Cardiovascular involvement / toxicity

XII.n Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.af Coronary vasospasm - Vasospastic angina

XV. Pathology

XV.w Path: Pulmonary edema (see also II/IIa)

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.n Tumor lysis syndrome (TLS)

X. Systemic/Distant conditions, syndromes and reactions

X.o Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

XII. Cardiovascular involvement / toxicity

XII.q Pericarditis (see also under XIIc)

XVII. Infections & related conditions

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

XVII. Infections & related conditions

XVII.j Mucormycosis (pulmonary, tracheobronchial or systemic)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

V. Pleural and/or pericardial involvement

V.d Pleural/pericardial effusion, ANA positive (DI lupus)

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

XIII. Neoplastic conditions

XIII.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

XV. Pathology

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.h Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.k Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.n Pulmonary alveolar proteinosis (PAP) (secondary)

I. Interstitial/parenchymal lung disease

I.v Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.w Rapidly progressive ILD/pulmonary fibrosis (a.k.a. Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.x Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.y Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.au The chemotherapy lung

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.c ARDS and the hemolytic-uremic syndrome (HUS)

II. Pulmonary edema - Acute lung injury - ARDS

II.d Pulmonary edema, cardiogenic

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.k Bronchiectasis

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.f Pneumothorax

V. Pleural and/or pericardial involvement

V.ab Pneumothorax, bilateral

VI. Pulmonary vasculopathy

VI.c Pulmonary veno-occlusive disease

VI. Pulmonary vasculopathy

VI.f Hemolytic and uremic syndrome (HUS). See also under Xaf

VII. Mediastinal involvement

VII.h Pneumomediastinum

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.f Hiccup

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.o Pneumorachis

X. Systemic/Distant conditions, syndromes and reactions

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.n Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.w Cavitation/necrosis of lung tumor or metastases

XII. Cardiovascular involvement / toxicity

XII.b Valvular heart disease and/or dysfunction

XII. Cardiovascular involvement / toxicity

XII.g Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.bl Atrial fibrillation

XIII. Neoplastic conditions

XIII.a Lung cancer

XIII. Neoplastic conditions

XIII.d Malignant mesothelioma (pleural, pericardial)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also pattern If)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.i Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XV. Pathology

XV.l Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XV. Pathology

XV.ak Path: Pulmonary veno-occlusive disease (PVOD)

XV. Pathology

XV.am Path: Thrombosis in pulmonary arterioles/venules

XVI. Imaging

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.af Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.bf Imaging: Tumoral cavitation

XVI. Imaging

XVI.bl Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVI. Imaging

XVI.bw Imaging: Air or an air crescent around lung tumor or metastase(s)

XVII. Infections & related conditions

XVII.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XVII. Infections & related conditions

XVII.e Pneumocystis jiroveci pneumonia

XVII. Infections & related conditions

XVII.r Fungal infection (pulmonary/extrapulmonary)

XVII. Infections & related conditions

XVII.af Reactivation of a prior pulmonary infection (TB, melioidosis)

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.g BAL: Atypical epithelial cells (at times poetically named

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

V. Pleural and/or pericardial involvement

V.b Eosinophilic pleural effusion

V. Pleural and/or pericardial involvement

V.c Pleural thickening - Fibrothorax

XI. Miscellaneous

XI.c Pleuritic chest pain

XI. Miscellaneous

XI.p Chest deformity: platythorax

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.ap Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

XVI. Imaging

XVI.ap Imaging: Pleural thickening w/wo rounded atelectasis

XVII. Infections & related conditions

XVII.q Viral pneumonia

II. Pulmonary edema - Acute lung injury - ARDS

II.p Respiratory distress or failure, not otherwise specified

IV. Airway involvement

IV.c Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

V. Pleural and/or pericardial involvement

V.u Eosinophilic pleuritis

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.b Pulmonary arterial hypertension

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.c Upper airway obstruction other than angioedema or hematoma

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.w Uvulitis, uvular edema

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.u Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.w Eosinophilia myalgia syndrome (EMS)

XI. Miscellaneous

XI.r Death following exposure or poisoning

XI. Miscellaneous

XI.bi Cyanide poisoning

XII. Cardiovascular involvement / toxicity

XII.w Asystole

XII. Cardiovascular involvement / toxicity

XII.ah Tachycardia

XV. Pathology

XV.z Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.d BAL: Gross or microscopic bleeding/hemorrhage

XXIV. Veterinary medicine

XXIV.i Veterinary: Respiratory/Ventilatory depression

XXVII. Esophageal involvement

XXVII.a Esophageal pathology (erosion, ulcer, tear, rupture, fistula)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.u Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.aa Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.aj Shrinking lung syndrome

I. Interstitial/parenchymal lung disease

I.ax Chronic pneumonitis

III. Pulmonary/alveolar/airway hemorrhage/bleeding

III.m Coagulopathy

IV. Airway involvement

IV.n Obstructive airway dysfunction (see also IVc, XVx)

IV. Airway involvement

IV.y Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

IV. Airway involvement

IV.ab Exacerbation or deterioration of preexisting COPD

IV. Airway involvement

IV.al Sputum production - Bonchorrhea - ‘Bronchitis’

V. Pleural and/or pericardial involvement

V.i Pleuritis (can cause chest pain)

V. Pleural and/or pericardial involvement

V.s Serositis - Polyserositis

VII. Mediastinal involvement

VII.a Lymphadenopathy (intrathoracic)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.t Vocal cord paresis/paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r Myasthenia gravis - Myasthenic-like syndrome

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ab Guillain-Barré (or GB-like) syndrome (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ac Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.m Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.s Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.am Immune-related adverse effect/toxicity

X. Systemic/Distant conditions, syndromes and reactions

X.an Cytokine release syndrome - Cytokine storm

X. Systemic/Distant conditions, syndromes and reactions

X.aw Connective tissue disease

X. Systemic/Distant conditions, syndromes and reactions

X.ay Polymyalgia rheumatica

X. Systemic/Distant conditions, syndromes and reactions

X.bi Temporal arteritis (Horton’s)

XI. Miscellaneous

XI.y Adrenal suppression

XI. Miscellaneous

XI.ag Vertebral compression fracture

XI. Miscellaneous

XI.au Graft vs. host disease in transplant recipients

XI. Miscellaneous

XI.av Deterioration of graft function in SOT recipients

XI. Miscellaneous

XI.ba Nonrespiratory AE of interest

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.e Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.r Heart failure (biventricular, congestive)

XII. Cardiovascular involvement / toxicity

XII.s Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.ai Cardiotoxicity

XII. Cardiovascular involvement / toxicity

XII.ax Necrotizing myocarditis (w/o evidence for CAD)

XII. Cardiovascular involvement / toxicity

XII.ba Sudden cardiac death

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

XV. Pathology

XV.v Path: Micronodular organizing pneumonia/BOOP

XV. Pathology

XV.x Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XV. Pathology

XV.ba Path: Granulomatous lymphadenopathy

XV. Pathology

XV.ca Path: Myocarditis

XV. Pathology

XV.co Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XV. Pathology

XV.cp Path: Pneumocyte vacuolization

XV. Pathology

XV.cw Path: Myocardial vasculitis

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.bh Imaging: F18-PET scan positive lympadenopathy

XVI. Imaging

XVI.bm Imaging: Avid pleural uptake on PET-scan

XVI. Imaging

XVI.bt Imaging: A subsolid lung nodule or nodules

XVII. Infections & related conditions

XVII.b Opportunistic pulmonary/systemic infections

XVII. Infections & related conditions

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b BAL: An excess proportion of neutrophils

IV. Airway involvement

IV.ag Bronchocentric granulomatosis

X. Systemic/Distant conditions, syndromes and reactions

X.az Hemophagocytic syndrome

XII. Cardiovascular involvement / toxicity

XII.h Eosinophilic myocarditis

XV. Pathology

XV.cc Path: Eosinophilic myocarditis

XV. Pathology

XV.cu Path: Bronchocentric granulomatosis

XXIV. Veterinary medicine

XXIV.g Veterinary: Cardiac arrhythmias